Mutual Of America Capital Management Has Decreased Unifi (UFI) Stake; Shorts at Aralez Pharmaceuticals Inchares (ARLZ) Raised By 36.55%

April 17, 2018 - By Winifred Garcia

Aralez Pharmaceuticals Inchares (NASDAQ:ARLZ) had an increase of 36.55% in short interest. ARLZ’s SI was 2.55M shares in April as released by FINRA. Its up 36.55% from 1.87M shares previously. With 554,100 avg volume, 5 days are for Aralez Pharmaceuticals Inchares (NASDAQ:ARLZ)’s short sellers to cover ARLZ’s short positions. The SI to Aralez Pharmaceuticals Inchares’s float is 4.91%. The stock increased 0.68% or $0.01 during the last trading session, reaching $1.48. About 215,767 shares traded. Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) has declined 41.74% since April 17, 2017 and is downtrending. It has underperformed by 53.29% the S&P500.

Mutual Of America Capital Management Llc decreased Unifi Inc. (UFI) stake by 17.22% reported in 2017Q4 SEC filing. Mutual Of America Capital Management Llc sold 27,160 shares as Unifi Inc. (UFI)’s stock rose 2.41%. The Mutual Of America Capital Management Llc holds 130,520 shares with $4.68M value, down from 157,680 last quarter. Unifi Inc. now has $632.91M valuation. The stock decreased 8.90% or $3.38 during the last trading session, reaching $34.59. About 331,949 shares traded or 448.33% up from the average. Unifi, Inc. (NYSE:UFI) has risen 34.05% since April 17, 2017 and is uptrending. It has outperformed by 22.50% the S&P500.

Mutual Of America Capital Management Llc increased Nmi Holdings Inc. (NASDAQ:NMIH) stake by 35,245 shares to 632,912 valued at $10.76 million in 2017Q4. It also upped Amgen Inc. (NASDAQ:AMGN) stake by 24,525 shares and now owns 112,711 shares. Honeywell International Inc (NYSE:HON) was raised too.

Analysts await Unifi, Inc. (NYSE:UFI) to report earnings on April, 25 before the open. They expect $0.42 earnings per share, down 16.00% or $0.08 from last year’s $0.5 per share. UFI’s profit will be $7.68M for 20.59 P/E if the $0.42 EPS becomes a reality. After $0.43 actual earnings per share reported by Unifi, Inc. for the previous quarter, Wall Street now forecasts -2.33% negative EPS growth.

Since February 2, 2018, it had 6 insider buys, and 0 sales for $3.45 million activity. 10,000 shares were bought by Bishop Robert J, worth $353,200 on Tuesday, February 27.

Investors sentiment decreased to 1.31 in 2017 Q4. Its down 0.39, from 1.7 in 2017Q3. It turned negative, as 7 investors sold UFI shares while 38 reduced holdings. 19 funds opened positions while 40 raised stakes. 14.23 million shares or 1.31% more from 14.05 million shares in 2017Q3 were reported. Gsa Cap Prtn Limited Liability Partnership stated it has 0.08% of its portfolio in Unifi, Inc. (NYSE:UFI). Envestnet Asset Inc stated it has 1,629 shares. Retail Bank Of Montreal Can holds 0% in Unifi, Inc. (NYSE:UFI) or 2,824 shares. Renaissance Technologies Ltd Llc has 0.01% invested in Unifi, Inc. (NYSE:UFI). Strs Ohio holds 3,500 shares or 0% of its portfolio. Jpmorgan Chase & reported 0% of its portfolio in Unifi, Inc. (NYSE:UFI). Ls Investment Advsrs Llc reported 604 shares. Cornerstone Advsr holds 0% of its portfolio in Unifi, Inc. (NYSE:UFI) for 116 shares. Northern Corp reported 505,771 shares or 0% of all its holdings. Louisiana State Employees Retirement Systems reported 7,300 shares stake. M&R Capital Mgmt invested in 1,000 shares. Blackrock Inc has invested 0% in Unifi, Inc. (NYSE:UFI). State Of Tennessee Treasury Department accumulated 0% or 12,107 shares. Balyasny Asset Management has invested 0% in Unifi, Inc. (NYSE:UFI). Rhumbline Advisers holds 0% or 38,800 shares in its portfolio.

Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical firm in the United States and Canada. The company has market cap of $95.26 million. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It currently has negative earnings. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization.

Unifi, Inc. (NYSE:UFI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts